Immune checkpoint alterations and their blockade in COVID-19 patients

Coronavirus disease 2019 (COVID-19) is a highly contagious disease that seriously affects people’s lives. Immune dysfunction, which is characterized by abnormal expression of multiple immune checkpoint proteins (ICs) on immune cells, is associated with progression and poor prognosis for tumors and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Jiaxiong, Li, Yangqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592141/
https://www.ncbi.nlm.nih.gov/pubmed/36311817
http://dx.doi.org/10.1097/BS9.0000000000000132
_version_ 1784814856822587392
author Tan, Jiaxiong
Li, Yangqiu
author_facet Tan, Jiaxiong
Li, Yangqiu
author_sort Tan, Jiaxiong
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a highly contagious disease that seriously affects people’s lives. Immune dysfunction, which is characterized by abnormal expression of multiple immune checkpoint proteins (ICs) on immune cells, is associated with progression and poor prognosis for tumors and chronic infections. Immunotherapy targeting ICs has been well established in modulating immune function and improving clinical outcome for solid tumors and hematological malignancies. The role of ICs in different populations or COVID-19 stages and the impact of IC blockade remains unclear. In this review, we summarized current studies of alterations in ICs in COVID-19 to better understand immune changes and provide strategies for treating COVID-19 patients, particularly those with cancer.
format Online
Article
Text
id pubmed-9592141
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95921412022-10-25 Immune checkpoint alterations and their blockade in COVID-19 patients Tan, Jiaxiong Li, Yangqiu Blood Sci Review Article Coronavirus disease 2019 (COVID-19) is a highly contagious disease that seriously affects people’s lives. Immune dysfunction, which is characterized by abnormal expression of multiple immune checkpoint proteins (ICs) on immune cells, is associated with progression and poor prognosis for tumors and chronic infections. Immunotherapy targeting ICs has been well established in modulating immune function and improving clinical outcome for solid tumors and hematological malignancies. The role of ICs in different populations or COVID-19 stages and the impact of IC blockade remains unclear. In this review, we summarized current studies of alterations in ICs in COVID-19 to better understand immune changes and provide strategies for treating COVID-19 patients, particularly those with cancer. Lippincott Williams & Wilkins 2022-08-01 /pmc/articles/PMC9592141/ /pubmed/36311817 http://dx.doi.org/10.1097/BS9.0000000000000132 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS). https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Tan, Jiaxiong
Li, Yangqiu
Immune checkpoint alterations and their blockade in COVID-19 patients
title Immune checkpoint alterations and their blockade in COVID-19 patients
title_full Immune checkpoint alterations and their blockade in COVID-19 patients
title_fullStr Immune checkpoint alterations and their blockade in COVID-19 patients
title_full_unstemmed Immune checkpoint alterations and their blockade in COVID-19 patients
title_short Immune checkpoint alterations and their blockade in COVID-19 patients
title_sort immune checkpoint alterations and their blockade in covid-19 patients
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592141/
https://www.ncbi.nlm.nih.gov/pubmed/36311817
http://dx.doi.org/10.1097/BS9.0000000000000132
work_keys_str_mv AT tanjiaxiong immunecheckpointalterationsandtheirblockadeincovid19patients
AT liyangqiu immunecheckpointalterationsandtheirblockadeincovid19patients

Ejemplares similares